ALT beat EPS expectations by 10.46%
Nov 12, 2024, 11:33 PM
0.00%
What does ALT do
Altimmune, a clinical-stage biopharmaceutical company in Gaithersburg, Maryland, develops peptide-based therapeutics for obesity and liver diseases, including the lead candidate pemvidutide. The company has completed Phase II trials for both pemvidutide and HepTcell, targeting metabolic dysfunction and hepatitis B.
Altimmune (ALT) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Altimmune's actual EPS was -$0.32, beating the estimate of -$0.36 per share, resulting in a 10.46% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.